[Skip to Navigation]
Views 1,631
Citations 0
Research Letter
Health Care Policy and Law
March 29, 2021

Frequency of First Generic Drug Approvals With “Skinny Labels” in the United States

Author Affiliations
  • 1Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
JAMA Intern Med. 2021;181(7):995-997. doi:10.1001/jamainternmed.2021.0484

Brand-name drug manufacturers in the US use several strategies to delay generic competition,1 including obtaining a thicket of patents to protect beyond a drug’s active ingredient and original use.2 Such patents can cover use of the drug for supplemental indications that the US Food and Drug Administration (FDA) approves after a medication is already on the market.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    FDA approved indication
    Linda Plizga, DO | Ascension St John Detroit
    Yes but if "skinny labels" don't include the indications then will they still be covered under insurance because then they won't be considered "FDA approved" for that indication?
    CONFLICT OF INTEREST: None Reported
    ×